posteriori / iStockphoto.com
16 February 2018Americas
Astellas Pharma expands portfolio by acquiring Universal Cells
Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
24 October 2016 Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018 Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Editor's picks
Editor's picks
Americas
24 October 2016 Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018 Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
24 October 2016 Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018 Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.